Skip to main content

Global In-vitro Colorectal Cancer Screening Tests Market 2019-2023 | Evolving Opportunities with Abbott & Danaher | Technavio

The global in-vitro colorectal cancer screening tests market size is poised to grow by USD 219.61 million during 2019-2023, according to a new report by Technavio, progressing at a CAGR of close to 6% during the forecast period. Request Free Sample Pages

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191122005412/en/

Technavio has announced its latest market research report titled global in-vitro colorectal cancer screening tests market 2019-2023. (Graphic: Business Wire)

Technavio has announced its latest market research report titled global in-vitro colorectal cancer screening tests market 2019-2023. (Graphic: Business Wire)

Read the 127-page research report with TOC on "In-vitro Colorectal Cancer Screening Tests Market Analysis Report by End-user (Hospitals, Clinical diagnostic laboratories, and Others) and Geography (Americas, APAC, and EMEA) 2019-2023".

The market is driven by the growing awareness programs and government initiatives for cancer screening. Also, the increased rate of product approval is anticipated to further boost the growth of the in-vitro colorectal cancer screening tests market.

The growing number of awareness programs and government initiatives will drive the market growth during the forecast period. Compulsory education and economic development are crucial in creating awareness about colorectal cancer screening. Early detection of colorectal cancer can improve outcomes. Mars Bleu was launched by NOVIGENIX as a national colorectal cancer awareness campaign and was dedicated to raising awareness about screening and preventing colorectal cancer in many countries. Moreover, in countries such as the US, government initiatives such as Colorectal Cancer Control Program and insurance policies like Medicaid and Medicare are working toward providing colorectal cancer screening tests to many patients.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.
View market snapshot before purchasing

Major Four In-Vitro Colorectal Cancer Screening Tests Companies:

Abbott

Abbott has business operations under various segments, which include established pharmaceuticals; nutritionals; diagnostics; and cardiovascular and neuromodulation. The company’s key offerings include RealTime mS9 Colorectal Cancer Assay, which is an automated laboratory test based on real-time PCR.

Danaher

Danaher offers analytical instruments, reagents, consumables, and software and services that hospitals, physicians’ offices, reference laboratories, and other critical care settings use to diagnose diseases. The company’s key offerings in the market includes Hemoccult ICT, which is offered with dry slide technology, to offer good sample stability.

QIAGEN

QIAGEN operates its business through two segments, namely consumables and related; and instrumentation. The company offers therascreen KRAS RGQ PCR Kit for the detection of colorectal cancer tumor samples, and is in compliance with the EU IVD Directive 98/79/EC.

Quest Diagnostics

Quest Diagnostics offers risk assessment services, healthcare information technology, diagnostic products, and clinical trials testing for life insurers, healthcare organizations, and clinicians. The company’s key offerings includes the ColoVantage test, which is offered as a molecular colorectal cancer detection method.

Siemens

Siemens has business operations under various segments, such as power and gas, energy management, building technologies, mobility, digital factory, process industries and drives, Siemens Healthineers, and Siemens Gamesa Renewable Energy. The company offers syngo.CT Colonography, a software module dedicated for the non-invasive evaluation of the entire colon for cancer detection.

Register for a free trial today and gain instant access to 17,000+ market research reports.
Technavio's SUBSCRIPTION platform

In-Vitro Colorectal Cancer Screening Tests End-Users Outlook (Revenue, USD Million, 2019-2023)

  • Hospitals
  • Clinical diagnostic laboratories
  • Others

In-Vitro Colorectal Cancer Screening Tests Regional Outlook (Revenue, USD Million, 2019-2023)

  • Americas
  • APAC
  • EMEA

Technavio’s sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com.

Contacts:

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email:media@technavio.com.
Website: https://www.technavio.com/

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.